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The emergence of new novel therapeutic agents which directly target molecules that are uniquely or abnormally
expressed in cancer cells (molecular targeted therapy, MTT) has changed dramatically the treatment of cancer in
recent years. The clinical benefit associated with these agents is typically limited to a subset of treated patients,
who in many cases are defined by a specific genomic mutations and expression lesion within their tumor cells.
All these new therapy modalities represent new challenges to radiologists as their mechanism of action and side
effect profiles differ from conventional chemotherapy agents. In this article we will discuss radiological patterns of
response to molecular targeted therapies MTT in lung cancer, typical and atypical radiological responses of targeted
molecular therapy for other intra thoracic malignancies, cardiopulmonary toxicity and other side effects of
molecular targeted therapy MTT in the thorax.
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The emergence of novel therapeutic agents that directly
target molecules that are uniquely or abnormally
expressed in cancer cells (molecular targeted therapy,
MTT) has changed dramatically the treatment of cancer
in recent years [1]. The clinical benefit associated with
these agents is typically limited to a subset of treated pa-
tients, who in many cases are defined by specific genomic
mutations and expression within their tumor cells. All
these new therapy modalities represent new challenges to
radiologists as their mechanism of action and side effect
profiles differ from conventional chemotherapy agents [2].
In this article we will discuss radiological patterns of re-
sponse to MTT in lung cancer, typical and atypical radio-
logical responses of targeted molecular therapy for other
intrathoracic malignancies, cardiopulmonary toxicity and
other side effects of MTT in the thorax.* Correspondence: fsouza@umc.edu
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The role of MTT is to reduce or inhibit proliferative activ-
ity in cancer cells and block intracellular signaling path-
ways, blocking specific enzymes responsible for cancer
growth and proliferation. Among these important MTT
agents approved by the US Food and Drug Administration
(FDA) are imatinib mesylate (Gleevec®), approved to treat
gastrointestinal stromal tumor, trastuzumab (Herceptin®),
approved to treat certain types of breast cancer as well as
some types of gastric or gastroesophageal junction adeno-
carcinomas, and everolimus (Afinitor®), approved to treat
patients with advanced kidney cancer whose disease has
progressed after treatment with other therapies. In the
highly vascular metastatic tumors hepatocellular carcin-
oma (HCC) and renal cell carcinoma (RCC), successful re-
sponse to anti-angiogenic therapy has been associated
with the use of sunitinib (Sutent®) and sorafenib (Nexavar®),
respectively. The response is assessed by decreased tumor
size, decreased tumor attenuation, and tumor necrosis on
the post-therapy contrast-enhanced computed tomography
(CT) studies [3].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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First-line chemotherapy for lung cancer often includes
a platinum-based drug (cisplatin or carboplatin) in
combination with another FDA-approved chemotherapy
drug (paclitaxel, docetaxel, etoposide, gemcitabine,
pemetrexed) [3]. However, in a subset of patients with
non-small-cell-lung cancer (NSCLC), there is overex-
pression of epidermal growth factor receptor (EGFR).
Stimulation of the EGFR pathway leads to a series of
intracellular events culminating in increased mitotic
and growth potential, increased ability to metastasize,
and increased angiogenesis (new blood vessel forma-
tion) in the cancer cells.
Many factors that correlate with favorable response
occur in patients with particular clinical characteristics,
such as a higher frequency of EGFR mutations (which
themselves appear to be closely associated with higher
likelihood of response to EGFR inhibitors) among Asians
vs. non-Asians, women vs. men, never-smokers vs. current
or prior smokers, and/or patients with adenocarcinomas
vs. squamous histology tumors [4]. New developments in
the management of NSCLC include more aggressive sur-
gical techniques, the use of neoadjuvant chemoradiation
prior to surgery and use of molecular targeted therapeutic
agents [4-7]. The MTT agents currently FDA approved
for lung cancer are gefitinib and erlotinib. These MTT
agents have shown efficacy in first and second-line treat-
ment regimens as monotherapy or in combination with
conventional chemotherapy agents [7].
Radiological assessment of response to treatment in
cancer
Radiological assessment of response to treatment in lung
cancer can be further divided into typical and atypical
patterns of response. Typical patterns of response in-
clude: A) decrease in tumor size, B) decrease in vascular-
ity (e.g. anti-angiogenic agent effect), C) presence of
cavitary changes within the mass, and D) decrease inA
Figure 1 77 year old male with multifocal bronchoalveolar cell carcin
therapy with decrease in size of right peri hilar mass. A. Infiltrative con
of the right lower lobe. B. After 2 cycles of therapy with Tarceva there is sig
in the medial aspect of the right lower lobe. Fibrosis due to post treatmenmetabolism when F18fluorodeoxyglucose (FDG)- posi-
tron emission tomography (PET)/CT is used to evaluate
treatment response. Atypical patterns of response in-
clude: A) increase in the size of a mass with decreased
tracer uptake, B) presence of intralesional and/or perile-




A. Decrease in tumor sizeoma o
solida
nifica
t chanHistopathology is often used as the reference
standard for assessing the response to primary
chemotherapy in lung cancer. However, there is no
single definition of a histopathologic response, and
response criteria vary among studies. Most
commonly, a pathologic complete response is defined
by the absence of residual invasive tumor [8,9]. Other
response classifications include changes in tumor
cellularity and the presence of regressive changes in
residual tumor tissue [10] (Figures 1 and 2).
In radiology, is generally accepted that a decrease in
tumor size correlates with treatment effect; as a
result, imaging was adopted for lesion measurement
in the World Health Organization (WHO) criteria
in 1979. However, because of some limitations of the
WHO criteria, the Response Evaluation Criteria in
Solid Tumors (RECIST) was introduced in 2000.
Subsequently in October 2008 at the 20th EORTC-
NCI-AACR Symposium on Molecular Targets and
Cancer Therapeutics (Geneva, October 2008) a
New Response Evaluation Criteria in Solid Tumors:
Revised RECIST Guidelines (version 1.1) was
adopted [Table 1].
Both WHO and RECIST make use of anatomic
imaging, predominantly CT, to obtain measurements
of reference tumor lesions before and afterB
n erlotinib (Tarceva) showing marked interval response to
tive opacity involving the peri hilar region and the medial aspect
nt reduction in the tumor burden with minimal residual opacity
ges in the RLL.
A B
Figure 2 65 year old female with NSCLC and metastatic breast mass. A. Large heterogeneous soft tissue mass in the right breast is seen
consistent with metastatic NSCLC. B. After 4 cycles of chemotherapy with Tarceva there is significant decrease in the size of the metastatic mass
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However, functional imaging such as dynamic
contrast-enhanced magnetic resonance imaging
(DCE-MRI), perfusion CT and PET imaging have
been found to be more useful than morphological
changes in the assessment of tumor response [11].
Goudarzi et al [12]. in their retrospective analysis
of 630 patients with biopsy proven lung cancer
demonstrated that patients with pure bronchoalveolar
carcinoma (BAC) exhibit a lower FDG uptake and
lower tumor attenuation compared with those with
adenocarcinoma.
B. Decrease in tumor vascularity
Tumor vascularity can be assessed by measuring
blood flow kinetics using dynamic contrast
enhancement either with dual energy CT or
perfusional MRI. Subjective evaluation using
changes in tumor attenuation and tumor
vascularization, in addition to changes in tumor size,
is considered a good way to evaluate response by
computed tomography [13] (Figure 3). Measuring
Hounsfield units can serve as a surrogate of tumor
vascularity as tumors decrease in density due to
necrosis as they respond to therapy. Early clinical
trials have indicated, however, that conventionalble 1 Tumor response criteria— WHO, RECIST 1.0 and RECIS
HO RECIST 1.0
particular number of lesions specified Requires 10 targets per
measuring the tumor bu
dimensionally measurable lesion; no stipulation of
inimal size of the lesion
Measures the long axis
other lesions
% decrease in target lesions, without a 25%
crease in any one target lesion; confirmed at 4 wk
Defines progression as a
States that disease prog
measurable disease “mu
States that confirmation
version only if responseimaging strategies that use tumor size or other
structural criteria may not be suitable for
monitoring the effects of anti-angiogenesis drugs
[14]. An effective imaging strategy for assessing
tumor vascularity would also be of value to monitor
“anti-angiogenesis” drugs that aim to halt cancer
progression by suppressing the tumor blood supply.
Perfusion CT is potentially well suited to monitoring
tumor response to anti-angiogenesis agents [15].
Dynamic enhanced CT techniques using quantitative
enhancement parameters may provide a tool to
evaluate the heterogeneity of tumor vascularity and
angiogenesis and CT measurements of perfusion
have been shown to be reproducible and have been
validated against a range of reference methods
[15-25].
C. Cavitation
Cavitation has been commonly associated with
squamous subtypes and can be seen occasionally in
adenocarcinoma. Bevacizumab (Avastin) is a
humanized monoclonal antibody against vascular
endothelial growth factor (VEGF) that has been
associated with cavitation in primary and metastatic
lung cancer. Trials of VEGF inhibitors have shown




Requires only five targets (two per organ).
of lymph nodes as for Measures the short axis of lymph nodes
and long axis for other lesions




Expands that definition to convey an
impact on the overall burden of disease.
is required but in new
is primary endpoint
Includes a new section that incorporates a
comment on FDG PET interpretation
A B
Figure 3 68 year old male with metastatic thyroid cancer. CT scan with contrast (Figure A) shows hyper vascular mediastinal nodes (arrow)
consistent with metastatic disease. CT scan obtained after 2 cycles of Gefitinib (Figure B) demonstrates decrease in the attenuation of mediastinal
nodes (arrow) reflecting desvascularization, with a thin rim of residual peripheral enhancement.
Souza et al. Cancer Imaging 2014, 14:26 Page 4 of 13
http://www.cancerimagingjournal.com/content/14/1/26central cavitation [26]. It has been postulated that
cavitation occurs through central necrosis of lesions
after inhibition of angiogenesis. Marom et al [27]
described a retrospective single-institution experience
of 124 patients treated with various angiogenesis
inhibitors in which 14% of patients developed
cavitation. A potential link between clinically relevant
pulmonary hemorrhage and cavitation has been
raised by studies of bevacizumab warrants further
investigation, however (Figures 4 and 5).
D. Decreased metabolism
Frequently, there is a discrepancy between the
anatomic appearance and the metabolic activity of
the tumor during evaluation of response to anti-
angiogenic drugs. Changes in tumor size do not
necessarily correlate with changes in tumor viability
and outcome [28]. Therefore, it might be more
appropriate to assess tumor response by metabolic
activity, which can be measured by FDG uptake on
PET or [18 F] FDG PET/CT. Decrease in FDG
uptake after treatment may prove to be a better
indicator of a favorable response rather than change
in tumor size (Figure 6).A
Figure 4 65 year old female with NSCLC. Initial CT scan shows large soft tissue
(Avastin) the mass demonstrates typical antiangiogenesis effect with peripheral a
the mass (Figure 4B).Hicks et al [28] evaluated aggregated data on the use
of 18 F-FDG PET and PET/CT in therapeutic
response assessment in NSCLC and the data
strongly indicated that a reduction in tissue 18
F-FDG uptake, measured at whatever time after
treatment, is more likely to be associated with both
a pathologic response and improved survival than
when there was no evidence of decreased uptake by
the tissue.Atypical response patterns
A. Increase in the size of a mass with decreased
metabolism
The overall increase in size and decrease in tracer
uptake in a mass is a phenomenon that has been
extensively described in gastrointestinal stromal
tumor treated with imatinib mesylate (Gleevec),
reflecting therapy response [13]. In our series we
also observed similar findings in patients with lung
cancer. Once the patient is treated, the tumor
usually decreases in size upon response. In some
responding tumors, the tumor size increases as aB
mass in the RML (Figure 4A). After 3 cycles of Bevacizumab
nd cavitation associated with mild overall decrease in the size of
A B
Figure 5 58 year old female with metastatic breast cancer. A. demonstrates multiple metastatic pulmonary nodules in both lungs. B. After 3
months of bevacizumab (Avastin) therapy there has been remarkable decrease in size and cystic change in lung metastases.
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necrosis, or myxoid degeneration. The attenuation
of the tumor decreases significantly, as the tumor
becomes homogeneous.
B. Presence of intralesional and/or perilesional
hemorrhage with stable or increased size of the
mass.A
C
Figure 6 56 year old female with NSCLC treated with Bevacizumab. A
mass in the right middle lobe extending to the right hilar region demonst
Bevacizumab (Avastin) there has been interval development of pulmonary
central cavitation and decrease in FDG uptake in the central portion of the
adenopathy are seen.Challenges and future directions
The discovery of the correlation of EGFR mutations and
response to EGFR TKI therapy has demonstrated that
molecular typing of tumors to guide therapy selection
for lung cancer is possible. Prospective trials will need to
validate the feasibility and efficacy of selecting therapy
based on tumor molecular profiles. Also, numerousB
D
-B. Computed tomography and PET-CT demonstrating soft tissue
rating significantly increased tracer uptake. C-D. After 2 cycles of
cavitation within the central portion of the RML mass. PET-CT showing
mass (arrow). Persistent peripheral soft tissue and right hilar
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and future studies will need to identify molecular and
clinical tools to guide the use of these agents, particu-
larly in combination with current therapies such as
surgery, radiation, cytotoxic chemotherapy, and other
targeted therapies.The role of computed tomography-guided core-needle
biopsy in demonstrating epidermal growth factor receptor
mutations in patients with non-small-cell lung cancer
The use of surgical specimens to identify EGFR mutations
obtained is invasive, expensive, and increases morbidity
and mortality. Alternatively, prior reports on EGFR muta-
tion analysis in nonsurgical materials such as biopsy speci-
mens, pleural effusions, and serum have noted problems
of contamination by non-target normal cells within the
samples [29-32]. CT-guided coaxial core-needle biopsy of
the lung has been proven to have high diagnostic accur-
acy, sensitivity, specificity, and negative predictive values
in advanced NSCLC and enables the acquisition of suffi-
cient tissue for EGFR gene mutation analysis [33].Pulmonary toxicity from novel antineoplastic agents
Antineoplastic agent-induced pulmonary toxicity is com-
plex and a diagnosis of exclusion [34]. Similarly, the
pathogenesis of antineoplastic agent-induced lung injury
is poorly understood and several mechanisms have been
suggested, including direct injury to pneumocytes (chem-
ical alveolitis) or the alveolar capillary endothelium and
the subsequent release of cytokines and recruitment of
inflammatory cells [35-37].
Other causes of respiratory failure, including pneumo-
nia, cardiogenic pulmonary edema, and diffuse alveolar
hemorrhage, should be excluded. These conditions are
not easily differentiated based on clinical presentation and
radiographic findings. Furthermore, as patients usuallyA
Figure 7 66 year old male with post transplant lymphoproliferative d
abnormality with bilateral effusions, ground glass attenuation, thickened in
diffuse parenchymal uptake of FDG in keeping with a diffuse inflammatoryreceive multiple antineoplastic agents, it is usually difficult
to identify the culprit agent.
The clinical and radiologic manifestations of these
drugs generally reflect the underlying histopathologic
processes and include diffuse alveolar damage (DAD),
interstitial pneumonitis, cryptogenic organizing pneumo-
nia (COP), eosinophilic pneumonia, obliterative bron-
chiolitis, pulmonary hemorrhage, edema, hypertension,
or veno-occlusive disease. Intra-thoracic and extra pul-
monary side effects of these drugs include skin thicken-
ing, pleural effusions and thromboembolism.
Diffuse alveolar damage
DAD is a common manifestation of drug-induced lung
injury that results from necrosis of type II pneumocytes
and alveolar endothelial cells [35]. DAD is divided into
an acute exudative phase and a late reparative or prolif-
erative phase.
Drugs that may cause DAD include gefitinib, an oral
EGFR tyrosine kinase inhibitor that is active against
NSCLC, ovarian, colon, head and neck, and breast can-
cers. Gefitinib-induced lung toxicity usually occurs within
the first 90 days of treatment. Interstitial pneumonitis,
alveolar hemorrhage, and pulmonary fibrosis have been
described [38-43].
Chest radiographs show bilateral heterogeneous or
homogeneous opacities, often distributed in the mid
and lower lung. High-resolution CT in early DAD typic-
ally shows scattered or diffuse areas of ground-glass
opacity. When progressive fibrosis develops, marked
architectural distortion and honeycomb lung can occur
(Figure 7).
Interstitial pneumonitis
Interstitial pneumonitis is characterized by areas of scat-
tered expansion of the interstitium by inflammatory cells,
mild interstitial fibrosis, and reactive hyperplastic type IIB
isorder on rituximab. A. CT scan of the chest shows diffuse
terstitium and coarse linear parenchymal bands. B. PET image shows
process. Biopsy revealed diffuse alveolar damage.
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lung cancer that can cause interstitial pneumonitis include:
erlotinib, trastuzumab, temsirolimus, everolimus and
gefitinib.
Erlotinib (Tarceva) is indicated for the treatment of pa-
tients with locally advanced or metastatic NSCLC. Vahid
and Esmaili [44] described two cases of erlotinib-induced
pneumonitis that resulted in respiratory failure. The pa-
tients presented 4 to 6 days after the initiation of erlotinib
therapy with fever, cough, and hypoxemia.
Trastuzumab is a humanized monoclonal antibody
that selectively binds to the human EGFR (HER)-2 pro-
tein, indicated for the treatment of metastatic breast
cancers with over expression of HER-2 protein. The in-
cidence of trastuzumab-induced pneumonitis is 0.4 to
0.6%. Trastuzumab-induced pneumonitis may present
with rapidly progressive pulmonary infiltrates and
respiratory failure. Infusion-related symptoms, includ-
ing hypotension, angioedema, bronchospasm, dyspnea,
fever, chills, and urticaria, have been reported to
occur in about 15% of patients. Severe episodes of
hypotension, bronchospasm, and hypoxemia were also
observed [45-49].
Temsirolimus is a rapamycin analog that is active
against renal cell carcinoma, endometrial carcinoma,
breast cancer, glioblastoma multiforme, and gastrointes-
tinal neuroendocrine tumors. Interstitial pneumonitis is
a non–dose-dependent complication of temsirolimus.
Interstitial pneumonitis has been reported in 1 to 36% of
patients and the onset of pneumonitis usually takes place
within 16 weeks (range 2 to 16 weeks) after temsiroli-
mus treatment [50,51].
Everolimus is an mTOR inhibitor that has been
used as an investigational antineoplastic agent (e.g.
for the treatment of sarcoma or renal cell cancer). Al-
though clinical data in patients with malignancy are
sparse, there have been previous reports of interstitialA
Figure 8 Interstitial Pneumonitis 58 year old male with NSCLC on bev
in the posterior segment of the right upper lobe. B: Post treatment CT sho
interval development of ground glass attenuation, interstitial thickening an
pneumonitis.pneumonitis with everolimus in heart transplant re-
cipients [52].
Rituximab was first approved for the treatment of low-
grade follicular lymphoma, and is now also approved for
high-grade lymphomas, while it has also been used in
other hematological diseases. The mechanism of action
targets CD20+ B lymphocytes. Although rituximab-
induced lung injury is rare, it has been well documented
[53-56].
Interstitial pneumonitis has been reported with rituxi-
mab monotherapy, thus proving the potential of this
agent for lung injury. In all cases lung toxicity resolved
after steroid treatment, with no late sequelae. Neverthe-
less, it should be mentioned that concomitant adminis-
tration of steroids may not prevent the occurrence of
pneumonitis [53].
Radiological findings on chest radiographs in interstitial
pneumonitis usually show diffuse heterogeneous opacities
throughout both lungs. Areas of consolidation may also
be present [57] (Figure 8). Early high-resolution CT scans
may show only scattered or diffuse areas of ground-glass
opacity and centrilobular opacities (Figure 9) [58]. Later,
findings of fibrosis (traction bronchiectasis, honeycomb-
ing) predominate in a basal distribution.Cryptogenic organizing pneumonia
COP is a nonspecific histopathologic pattern of lung in-
jury characterized by the proliferation of immature fibro-
blastic plugs within the respiratory bronchioles, alveolar
ducts, and adjacent alveolar spaces [59]. Affected patients
present with progressive dyspnea, dry cough, and fever.
Trastuzumab treatment has been reported to be a causa-
tive agent of COP. Infusion-related symptoms, including
hypotension, angioedema, bronchospasm, dyspnea, fever,
chills, and urticaria, have been reported to occur in about
15% of patients.B
acizumab. A: Pre treatment images demonstrate consolidative mass
ws marked reduction in size of a posterior segment RUL mass but with
d parenchymal bands. Biopsy was performed and showed Interstitial
A B
Figure 9 Interstitial pneumonitis. A and B: Axial and Coronal CT scan of the chest demonstrates diffuse areas of ground glass opacity
predominantly involving the upper lobes associated with centrilobular nodules. There has been sparing of the lower lobes consistent with
Rituximab induced interstitial pneumonitis.
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erogeneous and homogeneous opacities, which are typic-
ally peripheral in distribution and are equally distributed
between the upper and lower lobes. CT often shows as-
sociated poorly defined nodular areas of consolidation,
centrilobular nodules and “tree-in-bud opacities”, and
bronchial dilatation [59]. The pattern of parenchy-
mal opacity usually follows the bronchovascular bundle
(Figure 10). Patients with COP typically respond well to
cessation of drug therapy, but the patient may also re-
quire the administration of corticosteroids to improve
the radiological and clinical picture.
Eosinophilic pneumonia
Eosinophilic pneumonia is characterized by alveolar septal
thickening and infiltration by eosinophils, lymphocytes,
and plasma cells [60]. Causative drugs are trastuzumab
and oxaliplatin. Affected patients typically present with
progressive dyspnea, dry cough, and occasionally fever.
Peripheral eosinophilia and elevated immunoglobulin E
levels are common.A
Figure 10 COP. A and B: CT scan shows associated poorly defined nodula
bundle. Presence of centrilobular nodules and associated bronchial dilatat
pneumonia).Chest radiographs show homogeneous opacities that
typically have a peripheral and upper lobe distribution
with sparing of the central portions of the lung (Figure 11).
CT can be useful for demonstrating the peripheral nature
of the pulmonary opacities. Patients with eosinophilic
pneumonia caused by drug therapy usually respond well
to cessation of the therapy but the administration of corti-
costeroids may also be required.Pulmonary hemorrhage
Diffuse pulmonary hemorrhage is an uncommon compli-
cation with former chemotherapy regimens, but has be-
come more common with the introduction of new MTT
and anti-angiogenic agents. Pulmonary hemorrhage and
hemoptysis have been reported in 2.3% of patients with
nonsquamous NSCLC on bevacizumab (Avastin) therapy
[61-63]. Severe hemoptysis and pulmonary hemorrhage
associated with bevacizumab therapy is more common in
patients, with squamous cell carcinoma being reported in
up to 31% of patients.B
r areas of consolidation and cavitation along the bronchovascular
ion. Findings are consistent with COP (Cryptogenic organizing
A B
Figure 11 Eosiniphilic pneumonia. A and B. Thin-section (1-mm collimation) CT scan (lung windowing) shows multifocal patchy areas of
ground-glass opacity and consolidation predominantly located in the periphery of upper lobes. Findings are consistent with Eosiniphilic
pneumonia.
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neous and homogenous opacities. Focal consolidation is
a less common finding. High-resolution CT usually
shows scattered or diffuse areas of ground-glass opacity
with intralobular septal thickening (crazy paving pat-
tern), which can mimic atypical infection and edema
(Figure 12).
Pulmonary edema and fluid retention
The pathogenesis of antineoplastic agent-induced pul-
monary edema is poorly understood and has been sug-
gested to be due to direct injury to pneumocytes
(chemical alveolitis) or the alveolar capillary endothe-
lium and the subsequent release of cytokines, which in-
duce pulmonary edema due to leaky capillaries. Drugs
that may lead to increased permeability and subsequent
edema include imatinib, dasatinib and rituximab.
Imatinib is a potent tyrosine kinase inhibitor, which is
mainly used in the treatment of chronic myelogenous
leukemia (CML) and is also effective in patients withA
Figure 12 71 year old female with NSCLC on an erlotinib. A: Initial CT
pleural surface. B: CT scan obtained 2 months later demonstrates cavitation
surrounding ground glass opacities secondary to intralveolar hemorrhagegastrointestinal stromal tumor (GIST). Although most
cases of imatinib-induced pulmonary adverse events have
been reported in patients with CML, there have been
cases of dyspnea during imatinib therapy, most often re-
lated to fluid retention and pulmonary edema [64].
Dasatinib is a potent inhibitor of SRC/ABL kinase in-
hibitor used in the treatment of CML in patients who
had disease resistant to or who could not tolerate ima-
tinib [65]. A study by Kantarjian et al [66]. compared
dasatinib to imatinib and demonstrated that superficial
edema (42% versus 15%) and fluid retention (45% versus
30%) were more common in the imatinib group, while
pleural effusion (Figure 13) was more common with
dasatinib (17% versus 0%).
Characteristic findings of pulmonary edema on chest
radiographs include pulmonary vascular redistribution,
poor definition of pulmonary vascular markings, septal
(Kerley B) lines, and pleural effusions that may or may
not be associated with cardiomegaly (Figure 14). On
high-resolution CT, findings of patchy areas of ground-B
shows a large and lobulated left upper lobe mass extending to the
within the central portion of the mass with development of
(arrow).
A B
Figure 13 Dasatinib induced effusion. A. 72 year old male with CML with disease breakthrough on imatinib, 2 weeks after the switch to
dasatinib. PA CXR shows bilateral effusions. B. After dose reduction 1 month later, there was interval resolution of bilateral pleural effusions.
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and interlobular interstitial thickening, are seen in the
majority of patients with pulmonary edema.
Effusions
Pulmonary complications are uncommon and are usually
associated with a fluid retention syndrome. The manifesta-
tions from the lungs are pleural effusions and pulmonary
edema [67,68] seen in patients treated with imatinib and
dasatinib. It seems that these drugs are associated with rare
but well documented lung toxicity and this should be taken
into consideration in the differential diagnosis of otherwise
unexplained pleural effusions.
Thromboembolic manifestations
VEGF antagonism could cause decreased matrix deposition
in the supporting layers of vessels; therefore, the finalA
Figure 14 Imatinib induced pulmonary edema. A. CT scan on the ches
base with no evidence of pleural effusion. B. Restaging CT scan obtained 1
dose reduction.picture of anti-VEGF therapy might consist of increased
frequency of thrombotic events, as a result of tissue factor
activation secondary to the exposure of the subendothelial
collagen.
In a randomized phase II study evaluating the efficacy
and safety of bevacizumab in patients with previously
untreated advanced colorectal cancer [61,69,70], venous
thromboembolism was the most significant adverse
event, together with hypertension, proteinuria, and epi-
staxis. Bevacizumab has been also associated with in-
creased risk of pulmonary embolism [62,63] (Figure 15).
More recently, two small molecules blocking the
VEGF receptor (VEGFR) have shown promising results
in the treatment of renal cell carcinoma and gastrointes-
tinal stromal tumors (GISTs): sorafenib (Nexavar; Bayer
Pharmaceuticals Corporation, West Haven, CT), ap-
proved by the FDA in 2005 as a second-line treatmentB
t demonstartes thickening of the interlobular septa in the right lung
month later shows resolution of the pulmonary edema after
Figure 15 39 year old male with glioblastoma multiformae on Bevacizumab. A. Coronal CT demonstrates multiple bilateral pulmonary
emboli (arrow). B. US Doppler of the right lower extremity demonstrates echogenic material completely filling the left popliteal vein (arrow) and
extending to the proximal left posterior tibial vein consistent with Deep Venous Thrombosis.
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and sunitinib (Sutent; Pfizer, Inc., New York), approved
in 2006 for patients with GIST previously treated with
imatinib and for advanced renal cell carcinoma as a
first-line treatment. Both of these agents have been
strongly associated with thromboembolic events [71].
Cardiac toxicity
Cardiac toxicity is one major concern related to trastuzu-
mab administration [71]. In 2002, a retrospective review
of phase II and phase III trials of trastuzumab that evalu-
ated the incidence and the characteristics of trastuzumab-
associated cardiac dysfunction [72], demonstrated thatA
Figure 16 58 year old female on trastuzumab (Herceptin). A. MUGA sc
EF has dropped significantly to 49% (Figure 16A). B. The ejection fraction re
Trastuzumab is known to cause this effect, which is worsened with concom27% of patients receiving trastuzumab and doxorubicin,
13% of patients treated with trastuzumab and paclitaxel,
and 3%–7% of patients undergoing therapy with trastuzu-
mab alone developed cardiac dysfunction (Figure 16).
Most of these patients were symptomatic (75%) and im-
proved with standard treatment for CHF (79%). Since
these results were published, trastuzumab combined with
anthracyclines has not been recommended outside clinical
trials. The pathophysiology of trastuzumab-related cardio-
toxicity has not yet been completely elucidated; however,
physiologic analysis revealed parameters of dilated cardio-
myopathy, including chamber dilation wall thinning, and
decreased contractility.B
an obtained after 3 months of therapy with Herceptin shows that the
covers to 72% (Figure 16B) 1 week after discontinuation of therapy.
itant anthracycline administration.
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New imaging modalities are available to assess treatment
response. PET have the ability to assess tissue viability
more precisely than CT and detect metastatic lesions that
would have been missed on conventional imaging. Other
functional imaging techniques, such as dynamic contrast-
enhanced magnetic resonance imaging (DCE-MRI) and
perfusion CT imaging, have been found to be more useful
than morphological changes in the assessment of tumor re-
sponse, although not frequently used in most institutions.
With the discovery and introduction of new MTT
agents, the treatment for a wide variety of cancers has
been revolutionized. As these treatments become in-
creasingly recognized as therapeutic options, physicians
who interpret imaging studies should be aware of differ-
ent patterns of response and possible side effects of
these new MTT agents.
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